Biohaven Pharmaceutical Holding Company Ltd
NYSE:BHVN

Watchlist Manager
Biohaven Pharmaceutical Holding Company Ltd Logo
Biohaven Pharmaceutical Holding Company Ltd
NYSE:BHVN
Watchlist
Price: 50.36 USD -3.95% Market Closed
Market Cap: 5B USD
Have any thoughts about
Biohaven Pharmaceutical Holding Company Ltd?
Write Note

Intrinsic Value

There is not enough data to reliably calculate the intrinsic value of BHVN.

The Intrinsic Value is calculated as the average of DCF and Relative values:

BHVN Intrinsic Value
Not Available
Base Case Scenario
How do you feel about BHVN?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Biohaven Pharmaceutical Holding Company Ltd

Provide an overview of the primary business activities
of Biohaven Pharmaceutical Holding Company Ltd.

What unique competitive advantages
does Biohaven Pharmaceutical Holding Company Ltd hold over its rivals?

What risks and challenges
does Biohaven Pharmaceutical Holding Company Ltd face in the near future?

Has there been any significant insider trading activity
in Biohaven Pharmaceutical Holding Company Ltd recently?

Summarize the latest earnings call
of Biohaven Pharmaceutical Holding Company Ltd.

What significant events have occurred
in Biohaven Pharmaceutical Holding Company Ltd over the past months?

Show all valuation multiples
for Biohaven Pharmaceutical Holding Company Ltd.

Provide P/S
for Biohaven Pharmaceutical Holding Company Ltd.

Provide P/E
for Biohaven Pharmaceutical Holding Company Ltd.

Provide P/OCF
for Biohaven Pharmaceutical Holding Company Ltd.

Provide P/FCFE
for Biohaven Pharmaceutical Holding Company Ltd.

Provide P/B
for Biohaven Pharmaceutical Holding Company Ltd.

Provide EV/S
for Biohaven Pharmaceutical Holding Company Ltd.

Provide EV/GP
for Biohaven Pharmaceutical Holding Company Ltd.

Provide EV/EBITDA
for Biohaven Pharmaceutical Holding Company Ltd.

Provide EV/EBIT
for Biohaven Pharmaceutical Holding Company Ltd.

Provide EV/OCF
for Biohaven Pharmaceutical Holding Company Ltd.

Provide EV/FCFF
for Biohaven Pharmaceutical Holding Company Ltd.

Provide EV/IC
for Biohaven Pharmaceutical Holding Company Ltd.

Show me price targets
for Biohaven Pharmaceutical Holding Company Ltd made by professional analysts.

What are the Revenue projections
for Biohaven Pharmaceutical Holding Company Ltd?

How accurate were the past Revenue estimates
for Biohaven Pharmaceutical Holding Company Ltd?

What are the Net Income projections
for Biohaven Pharmaceutical Holding Company Ltd?

How accurate were the past Net Income estimates
for Biohaven Pharmaceutical Holding Company Ltd?

What are the EPS projections
for Biohaven Pharmaceutical Holding Company Ltd?

How accurate were the past EPS estimates
for Biohaven Pharmaceutical Holding Company Ltd?

What are the EBIT projections
for Biohaven Pharmaceutical Holding Company Ltd?

How accurate were the past EBIT estimates
for Biohaven Pharmaceutical Holding Company Ltd?

Compare the revenue forecasts
for Biohaven Pharmaceutical Holding Company Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Biohaven Pharmaceutical Holding Company Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Biohaven Pharmaceutical Holding Company Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Biohaven Pharmaceutical Holding Company Ltd compared to its peers.

Compare the P/E ratios
of Biohaven Pharmaceutical Holding Company Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Biohaven Pharmaceutical Holding Company Ltd with its peers.

Analyze the financial leverage
of Biohaven Pharmaceutical Holding Company Ltd compared to its main competitors.

Show all profitability ratios
for Biohaven Pharmaceutical Holding Company Ltd.

Provide ROE
for Biohaven Pharmaceutical Holding Company Ltd.

Provide ROA
for Biohaven Pharmaceutical Holding Company Ltd.

Provide ROIC
for Biohaven Pharmaceutical Holding Company Ltd.

Provide ROCE
for Biohaven Pharmaceutical Holding Company Ltd.

Provide Gross Margin
for Biohaven Pharmaceutical Holding Company Ltd.

Provide Operating Margin
for Biohaven Pharmaceutical Holding Company Ltd.

Provide Net Margin
for Biohaven Pharmaceutical Holding Company Ltd.

Provide FCF Margin
for Biohaven Pharmaceutical Holding Company Ltd.

Show all solvency ratios
for Biohaven Pharmaceutical Holding Company Ltd.

Provide D/E Ratio
for Biohaven Pharmaceutical Holding Company Ltd.

Provide D/A Ratio
for Biohaven Pharmaceutical Holding Company Ltd.

Provide Interest Coverage Ratio
for Biohaven Pharmaceutical Holding Company Ltd.

Provide Altman Z-Score Ratio
for Biohaven Pharmaceutical Holding Company Ltd.

Provide Quick Ratio
for Biohaven Pharmaceutical Holding Company Ltd.

Provide Current Ratio
for Biohaven Pharmaceutical Holding Company Ltd.

Provide Cash Ratio
for Biohaven Pharmaceutical Holding Company Ltd.

What is the historical Revenue growth
over the last 5 years for Biohaven Pharmaceutical Holding Company Ltd?

What is the historical Net Income growth
over the last 5 years for Biohaven Pharmaceutical Holding Company Ltd?

What is the current Free Cash Flow
of Biohaven Pharmaceutical Holding Company Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Biohaven Pharmaceutical Holding Company Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
Biohaven Pharmaceutical Holding Company Ltd

Balance Sheet Decomposition
Biohaven Pharmaceutical Holding Company Ltd

Current Assets 511.3m
Cash & Short-Term Investments 436.9m
Receivables 7.5m
Other Current Assets 66.8m
Non-Current Assets 71.4m
PP&E 48.6m
Intangibles 19.8m
Other Non-Current Assets 3m
Current Liabilities 156.2m
Accounts Payable 17.3m
Accrued Liabilities 57.7m
Other Current Liabilities 81.2m
Non-Current Liabilities 42.7m
Other Non-Current Liabilities 42.7m
Efficiency

Earnings Waterfall
Biohaven Pharmaceutical Holding Company Ltd

Revenue
0 USD
Operating Expenses
-781.3m USD
Operating Income
-781.3m USD
Other Expenses
34.7m USD
Net Income
-746.6m USD

Free Cash Flow Analysis
Biohaven Pharmaceutical Holding Company Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

BHVN Profitability Score
Profitability Due Diligence

Biohaven Pharmaceutical Holding Company Ltd's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

27/100
Profitability
Score

Biohaven Pharmaceutical Holding Company Ltd's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

BHVN Solvency Score
Solvency Due Diligence

Biohaven Pharmaceutical Holding Company Ltd's solvency score is 67/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Average Altman Z-Score
67/100
Solvency
Score

Biohaven Pharmaceutical Holding Company Ltd's solvency score is 67/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BHVN Price Targets Summary
Biohaven Pharmaceutical Holding Company Ltd

Wall Street analysts forecast BHVN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BHVN is 66.54 USD with a low forecast of 55.55 USD and a high forecast of 84 USD.

Lowest
Price Target
55.55 USD
10% Upside
Average
Price Target
66.54 USD
32% Upside
Highest
Price Target
84 USD
67% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for BHVN?

Click here to dive deeper.

Dividends

Biohaven Pharmaceutical Holding Company Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for BHVN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

BHVN Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

BHVN News

Other Videos

Profile

Biohaven Pharmaceutical Holding Company Ltd Logo
Biohaven Pharmaceutical Holding Company Ltd

Country

United States of America

Industry

Biotechnology

Market Cap

4.7B USD

Dividend Yield

0%

Description

Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. The company is headquartered in New Haven, Connecticut and currently employs 928 full-time employees. The company went IPO on 2017-05-04. The firm has a portfolio of therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. The firm's Neuroinnovation portfolio includes NURTEC ODT (rimegepant) for the acute and preventive treatment of migraine and a pipeline of product candidates across five platforms: calcitonin gene related peptide (CGRP) receptor antagonism for the acute and preventive treatment of migraine as well as other pain-related disorders and non-migraine indications; glutamate modulation for obsessive-compulsive disorder (OCD); myeloperoxidase (MPO) inhibition for multiple system atrophy (MSA) and amyotrophic lateral sclerosis (ALS); Kv7 Ion Channel Activators (Kv7) to target indications including epilepsy, pain disorders and effective disorders; and Myostatin offers a natural protein that limits skeletal muscle growth.

Contact

CONNECTICUT
New Haven
215 Church St
+12034040410.0
biohavenpharma.com

IPO

2017-05-04

Employees

928

Officers

Chairman & CEO
Dr. Vladimir Coric M.D.
Chief Financial Officer
Mr. Matthew Buten
Chief Scientific Officer
Dr. Bruce D. Car DACVP, Ph.D.
Senior Vice President of Clinical Operations
Ms. Kimberly Gentile
Director of Regulatory Affairs & Operations
Ms. Deb Young
VP & Chief Accounting Officer
Mr. George C. Clark
Show More
Vice President of Investor Relations
Ms. Jennifer Porcelli
General Counsel & Chief Legal Officer
Mr. Warren Volles J.D.
President, GM of Biohaven Ireland & Chief Compliance Officer
Mr. Clifford Bechtold M.S.
Chief Commercial Officer of Rare Diseases
Mr. John Tilton
Show Less

See Also

Discover More